Ludwig Enterprises (Ludwig Enterprises) EBITDA Margin % : -12,269.23% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ludwig Enterprises's EBITDA for the three months ended in Mar. 2024 was $-1.60 Mil. Ludwig Enterprises's Revenue for the three months ended in Mar. 2024 was $0.01 Mil. Therefore, Ludwig Enterprises's EBITDA margin for the quarter that ended in Mar. 2024 was -12,269.23%.

Ludwig Enterprises EBITDA Margin % Historical Data

The historical data trend for Ludwig Enterprises's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises EBITDA Margin % Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

EBITDA Margin %

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-12,269.23

Competitive Comparison of Ludwig Enterprises's EBITDA Margin %

For the Medical Devices subindustry, Ludwig Enterprises's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ludwig Enterprises's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's EBITDA Margin % falls into.

Ludwig Enterprises EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Ludwig Enterprises's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.971	/	0
	=	%

Ludwig Enterprises's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.595	/	0.013
	=	-12,269.23 %

Ludwig Enterprises (OTCPK:LUDG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Ludwig Enterprises EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.